AU2013220139B2 - Hydrocortisone controlled release formulation - Google Patents

Hydrocortisone controlled release formulation Download PDF

Info

Publication number
AU2013220139B2
AU2013220139B2 AU2013220139A AU2013220139A AU2013220139B2 AU 2013220139 B2 AU2013220139 B2 AU 2013220139B2 AU 2013220139 A AU2013220139 A AU 2013220139A AU 2013220139 A AU2013220139 A AU 2013220139A AU 2013220139 B2 AU2013220139 B2 AU 2013220139B2
Authority
AU
Australia
Prior art keywords
hydrocortisone
adrenal
composition
composition according
delayed release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013220139A
Other languages
English (en)
Other versions
AU2013220139A1 (en
Inventor
Hiep Huatan
Richard Ross
Martin Whitaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Uk Ltd
Original Assignee
Neurocrine Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Uk Ltd filed Critical Neurocrine Uk Ltd
Publication of AU2013220139A1 publication Critical patent/AU2013220139A1/en
Application granted granted Critical
Publication of AU2013220139B2 publication Critical patent/AU2013220139B2/en
Assigned to Neurocrine UK Limited reassignment Neurocrine UK Limited Request to Amend Deed and Register Assignors: DIURNAL LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013220139A 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation Active AU2013220139B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1202433.7 2012-02-13
GBGB1202433.7A GB201202433D0 (en) 2012-02-13 2012-02-13 Controlled drug release
US201261599704P 2012-02-16 2012-02-16
US61/599,704 2012-02-16
US201261600958P 2012-02-20 2012-02-20
US61/600,958 2012-02-20
PCT/GB2013/050311 WO2013121184A1 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation

Publications (2)

Publication Number Publication Date
AU2013220139A1 AU2013220139A1 (en) 2014-08-07
AU2013220139B2 true AU2013220139B2 (en) 2017-08-31

Family

ID=45930017

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013220139A Active AU2013220139B2 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation

Country Status (29)

Country Link
US (2) US9750704B2 (enExample)
EP (1) EP2814469B1 (enExample)
JP (1) JP6293678B2 (enExample)
KR (1) KR102023559B1 (enExample)
CN (2) CN104105481A (enExample)
AU (1) AU2013220139B2 (enExample)
BR (1) BR112014020008B1 (enExample)
CA (1) CA2864031C (enExample)
CY (1) CY1123202T1 (enExample)
DK (1) DK2814469T3 (enExample)
ES (1) ES2792069T3 (enExample)
GB (2) GB201202433D0 (enExample)
HK (1) HK1203824A1 (enExample)
HR (1) HRP20200780T1 (enExample)
HU (1) HUE048904T2 (enExample)
IL (2) IL234061B (enExample)
IN (1) IN2014DN06808A (enExample)
LT (1) LT2814469T (enExample)
ME (1) ME03742B (enExample)
MX (1) MX361407B (enExample)
NZ (2) NZ715616A (enExample)
PL (1) PL2814469T3 (enExample)
PT (1) PT2814469T (enExample)
RS (1) RS60346B1 (enExample)
RU (1) RU2619869C2 (enExample)
SI (1) SI2814469T1 (enExample)
SM (1) SMT202000286T1 (enExample)
WO (1) WO2013121184A1 (enExample)
ZA (1) ZA201508728B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
WO2016196687A1 (en) * 2015-06-01 2016-12-08 Massachusetts Institute Of Technology System and method for neuroendocrine control
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
KR101982287B1 (ko) * 2019-01-04 2019-05-24 (주)청아굿푸드 천연 추출물 함유 서방성 제제 및 그 제조방법
KR20230131916A (ko) 2021-01-15 2023-09-14 갈벤타 아게 박동성 방출 카페인 제제
US11904046B1 (en) 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations
WO2025240605A1 (en) 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Combination treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065692A1 (en) * 2004-01-03 2005-07-21 University Of Sheffield Treatment
US20110189293A1 (en) * 2007-12-17 2011-08-04 CombinatoRx, Incoporated Therapeutic regimens for the treatment of immunoinflammatory disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
JPS6013711A (ja) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− コルチコステロイドを含有する浸透局所製薬組成物
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
ES2163000T3 (es) 1996-01-16 2002-01-16 Advanced Polymer Systems Inc Suministro topico de farmacos al tracto gastrointestinal inferior.
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
AU2000265525A1 (en) 2000-08-29 2002-03-13 Mepha Ag Medicament for treating intestinal diseases
NZ527832A (en) * 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
IL160217A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Compositions and methods to prevent abuse of opioids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
AU2002226955B2 (en) 2001-11-23 2006-04-27 Allergan Pharmaceuticals International Limited Pharmaceutical dosage form with multiple coatings
DE602004028497D1 (de) 2003-09-15 2010-09-16 Nycomed Gmbh Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
ES2400446T5 (es) * 2006-08-03 2017-03-13 Horizon Pharma Ag Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática
AU2007321111A1 (en) 2006-11-17 2008-05-22 Da Volterra Colonic delivery using Zn/pectin beads with a Eudragit coating.
EP2143424A4 (en) 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
GB0817120D0 (en) 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
NZ582836A (en) 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2010113177A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
JP2012522816A (ja) * 2009-04-07 2012-09-27 デュオコート ファーマ エービー 改良されたグルココルチコイド療法
KR20120110098A (ko) 2009-11-16 2012-10-09 에보니크 룀 게엠베하 고형 (메트)아크릴레이트 공중합체를 분산제에 의해 분산된 형태로 전환시키는 방법
IT1405012B1 (it) 2010-08-06 2013-12-16 Sofar Spa Composizioni di beclometasone dipropionato in microsfere gastroresistenti a rilascio modificato e processo per il loro ottenimento
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065692A1 (en) * 2004-01-03 2005-07-21 University Of Sheffield Treatment
US20110189293A1 (en) * 2007-12-17 2011-08-04 CombinatoRx, Incoporated Therapeutic regimens for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
HUE048904T2 (hu) 2020-08-28
CN110141557A (zh) 2019-08-20
IL234061A0 (en) 2014-09-30
MX2014009716A (es) 2015-01-14
CN104105481A (zh) 2014-10-15
CA2864031C (en) 2019-11-12
IL245546A0 (en) 2016-06-30
GB201302406D0 (en) 2013-03-27
SMT202000286T1 (it) 2020-07-08
JP2015506972A (ja) 2015-03-05
AU2013220139A1 (en) 2014-08-07
ME03742B (me) 2021-04-20
MX361407B (es) 2018-12-04
WO2013121184A1 (en) 2013-08-22
NZ627468A (en) 2016-02-26
RS60346B1 (sr) 2020-07-31
GB2502402A (en) 2013-11-27
BR112014020008A8 (pt) 2018-01-23
GB201202433D0 (en) 2012-03-28
ES2792069T3 (es) 2020-11-06
CY1123202T1 (el) 2021-10-29
HK1203824A1 (en) 2015-11-06
IN2014DN06808A (enExample) 2015-05-22
PL2814469T3 (pl) 2020-07-13
EP2814469B1 (en) 2020-04-08
LT2814469T (lt) 2020-05-25
US9750704B2 (en) 2017-09-05
KR20140121478A (ko) 2014-10-15
HRP20200780T1 (hr) 2020-10-02
GB2502402B (en) 2014-11-12
ZA201508728B (en) 2017-09-27
CA2864031A1 (en) 2013-08-22
BR112014020008B1 (pt) 2022-05-24
IL234061B (en) 2018-03-29
SI2814469T1 (sl) 2020-07-31
US20170296475A1 (en) 2017-10-19
NZ715616A (en) 2017-03-31
DK2814469T3 (da) 2020-05-04
KR102023559B1 (ko) 2019-09-23
EP2814469A1 (en) 2014-12-24
RU2619869C2 (ru) 2017-05-18
JP6293678B2 (ja) 2018-03-14
US10166194B2 (en) 2019-01-01
RU2014130866A (ru) 2016-04-10
PT2814469T (pt) 2020-05-22
US20140370113A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
US10166194B2 (en) Hydrocortisone controlled release formulation
CN1404389B (zh) 时控脉冲给药系统
CN101410094B (zh) 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
RU2504362C2 (ru) Системы доставки лекарственных веществ, включающие в себя слабоосновные лекарственные вещества и органические кислоты
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
JP7787190B2 (ja) センタナファジン製剤ならびにその製造および使用方法
CN107205954A (zh) 特别用于治疗注意力缺陷障碍的方法和组合物
JP2005521682A (ja) 結腸放出組成物
US10905662B2 (en) Methods for storing cysteamine formulations and related methods of treatment
US20170202856A1 (en) Treatment of adrenal insufficiency
ZA200505180B (en) Process for manufacturing sustained release microbeads containing venlafaxine HCI
CN117157079A (zh) 一种口服肠溶皮质类固醇的药物组合物
CA2370355A1 (en) Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
GB2510754A (en) Delayed release hydrocortisone composition
US20150086626A1 (en) Stable dosage forms of skeletal muscle relaxants with extended release coating

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: NEUROCRINE UK LIMITED

Free format text: FORMER NAME(S): DIURNAL LIMITED